Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q1 FY24 Earnings Presentation
18 slides from Eris Lifesciences's earnings presentation, Aug 7, 2023
Slide 1: Exchange filing cover letter: Investor Presentation
EY Entrepreneur of the year-2Q13 2013 • FROST & SULLIVAN Best Fraclices-2013 Pis Badness today/YES bank Excellence Awards-2013 Eris Eris Lifesciences Limited Date: 07 August 2023 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra K
Slide 2: Eris Lifesciences Limited Q1 FY24 Investor Presentation
Eris ERIS LIFESCIENCES LIMITED Q1 FY 24 INVESTOR PRESENTATION 7th Aug 2023 I- 1 tris
Slide 3: Strategic Investments of FY23 - Demonstrating Impact in FY24
STRATEGIC INVESTMENTS OF FY23 - DEMONSTRATING IMPACT IN FY24 Key strategic investment made in FY23…. ….Demonstrating impact in FY24 1 • Strategic entry into Dermatology; acquired Oaknet, • Oaknet’s Q1 EBIDTA margin inching towards overall Branded Glenmark brands & Reddy’s brands; acquisition Formula
Slide 4: Strategic Investments of FY23 - Demonstrating Impact in FY24 (Contd..)
STRATEGIC INVESTMENTS OF FY23 - DEMONSTRATING IMPACT IN FY24 (Contd..) Key strategic investment made in FY23…. ….Demonstrating impact in FY24 AM] 4 • Took calculated decisions to participate in • Sacubitril + Valsartan (Zayo): Relaunched in Jan ‘23; revenue ramped up to “at risk” opportunities in FY
Slide 5: Oaknet Business Successfully Integrated; Exciting Prospects in Derma
OAKNET BUSINESS SUCCESSFULLY INTEGRATED; EXCITING PROSPECTS IN DERMA • Oaknet operations successfully integrated into the mainstream business in Q1 FY24 • Delivering superior financial outcomes starting Q1 - EBIDTA margin ~ 35% • Completed the first quarter of stabilizing Glenmark & Reddy’s brands •
Slide 6: Strong Pipeline of First-in-Market Combinations Through Our Own R&D
STRONG PIPELINE OF FIRST-IN-MARKET COMBINATIONS THROUGH OUR OWN R&D r Candidates/ Therapy Development Status Commercialisation 2 FDCs in Oral Anti-diabetes Clinical Trials Q3 of FY24 • Active pipeline of 10 2 FDCs in Heart Failure & MI Clinical Trials Q4 of FY24 fixed dose combinations 2 FDCs to add
Slide 7: Strategic Priorities for FY24
STRATEGIC PRIORITIES FOR FY24 1 • Successful commercialization of our New Product Pipeline • Unprecedented launch pipeline seen in FY24 with • 4 mother brands coming through our own R&D programme • Re-launch of “at risk” products • New product opportunities in core therapies 2 • Deepen our presence
Slide 8: Branded Formulations Business Summary – Q1 FY24
BRANDED FORMULATIONS BUSINESS SUMMARY – Q1 FY24 Branded Formulations Revenue Branded Formulations YPM Highlights for Q1 FY24 INR Mn INR lakh p.m. 21% ------<' 20% • 21% yoy revenue growth in Branded 4,548 5.02 3,745 4.17 Formulations - 97% of total revenue • Includes Eris Lifesciences, Eris Therapeu
Slide 9: Consolidated Business Summary – Q1 FY24
CONSOLIDATED BUSINESS SUMMARY – Q1 FY24 Consolidated Op. Revenue Consolidated EBIDTA Consolidated Highlights for Q1 FY24 INR Mn IINR Mn 4,666 31% 1,697 • Operating revenue growth of 17% yoy 17% 1,292 (inclusive of EHPL) 3,986 • Gross Margin 83.2% - expands by 455 bps yoy Q1 FY23 Q1 FY24 Q1 FY23 Q1 F
Slide 10: Q1 FY24 - Consolidated Income Statement
Q1 FY24 - CONSOLIDATED INCOME STATEMENT Consolidated Q1 FY 24 Q1 FY 24 Q1 FY 23 INR Millions yoy GR • Q1 FY24 operating revenue grew by 17.1% to Sale of Products Other Operating Income 4,600 66 3,921 65 17.3% 0.9% INR 4,666 million Revenue from Operations 4,666 3,986 17.1% • Gross profit margin expa
Slide 11: Eris Ranks Among the Top-10 Fastest Growing Companies in MAT Jun'23
ERIS RANKS AMONG THE TOP-10 FASTEST GROWING COMPANIES IN MAT JUN’23 22.0 Eris has outperformed the IPM by 351 bps in MAT JUN’23 14.8 14.2 14.0 13.6 13.3 a 13.3 13.2 12.8 11.9 9.8 IPM LA RENON INTAS MACLEODS GLENMARK MANKIND TORRENT ERIS LS ABBOTT* FDC CIPLA Eris continues to rank among the Top-10 co
Slide 12: Our Anti-Diabetes Franchise – Healthy Growth in Mother Brands
OUR ANTI-DIABETES FRANCHISE – HEALTHY GROWTH IN MOTHER BRANDS , , Revenue from Diabetes Glimisave Mother Brand Zomelis Mother Brand (DPP4) 23.3% 686.1 303.2 108.3 9.3% 39.7% 556.6 77.5 277.5 MAT'22 MAT'23 MAT'22 MAT'23 MAT'22 MAT'23 Tendia Mother Brand (DPP4) Cyblex Mother Brand '1"1111111=11 Gluxit
Slide 13: Our Cardiovascular Franchise – Continued Momentum in Established Brands
OUR CARDIOVASCULAR FRANCHISE – CONTINUED MOMENTUM IN ESTABLISHED BRANDS r n Revenue from CVD Therapy* Eritel Mother Brand LN Bloc Mother Brand 465.1 17.8% 177.9 15.2% 15.0% 76.6 403.6 151.0 66.6 MAT'22 MAT'23 MAT'22 MAT'23 MAT'22 MAT'23 Olmin Mother Brand Crevast Mother Brand Atorsave Mother Brand 6
Slide 14: Key Growth Drivers for FY24 – FY26
KEY GROWTH DRIVERS FOR FY 24 – FY 26 1 Growth in Base Business • Our Top-20 power brands account for 70% of our revenues and have grown at 17% in FY23. 15 out of these brands are ranked among the Top-5 in their respective segments. We have • 4 brands with revenues of Rs. 100+ crore each • 6 brands w
Slide 15: Key Growth Drivers for FY24 – FY26 (Contd..)
KEY GROWTH DRIVERS FOR FY 24 – FY 26 (Contd..) • 3 Expansion of physician coverage • • We continue to make good progress in expanding our coverage of Specialists and Consulting Physicians in line with our expectations We added ~ 200 Reps to the Eris field-force in FY23 • 4 Therapeutic Diversificatio
Slide 16: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Name of Shareholder 30-Jun-23 31-Mar-23 30-Dec-22 Others DIIs 0.56% 10.74% *699 *572 *647 Promoters 52.86% 52.86% 52.70% 1 Chrys Capital (Emerald Investment Limited) 7.58% 7.58% 7.58% 2 UTI Mutual Fund
Slide 17: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 18: Thank You
Eris ERIS LIFESCIENCES LIMITED THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 17 Kris